Trichostatin A increases the TIMP-1/MMP ratio to protect against osteoarthritis in an animal model of the disease

Qu,Hao; Li,Jin; Wu,Li‑Dong; Chen,Wei‑Ping

doi:10.3892/mmr.2016.5523

Trichostatin A increases the TIMP-1/MMP ratio to protect against osteoarthritis in an animal model of the disease

Authors:
- Hao Qu
- Jin Li
- Li‑Dong Wu
- Wei‑Ping Chen
View Affiliations

Affiliations: Department of Orthopedic Surgery, The Second Affiliated Hospital of Zhejiang University Medical College, Hangzhou, Zhejiang 310009, P.R. China
Published online on: July 18, 2016 https://doi.org/10.3892/mmr.2016.5523
Pages: 2423-2430
Copyright: © Qu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The histone deacetylase inhibitor trichostatin A (TSA) has been demonstrated to alleviate certain symptoms associated with osteoarthritis (OA). However, the exact mechanisms underlying this protective effect remain to be elucidated. The present study therefore examined the effects of TSA on the expression levels of interleukin‑1β (IL‑1β)-induced matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases-1 (TIMP-1) in vitro and in vivo. In vitro, reverse transcription‑quantitative polymerase chain reaction was performed to investigate alterations in mRNA expression levels in TSA-treated chondrocytes in the presence or absence of IL‑1β; in addition, protein expression and acetylation levels were assessed by western blotting. In vivo, TSA was administered to rats by intra‑articular injection, following which the mRNA and protein expression levels were analyzed. In addition, macroscopic and histological observations were conducted. Chondrocytes treated with IL‑1β demonstrated increased mRNA and protein expression levels of MMP‑1, MMP‑3 and MMP-13, and decreased expression levels of TIMP‑1 mRNA and protein; these alterations were significantly attenuated by TSA treatment. In addition, increased MMPs and decreased TIMP‑1 expression levels were observed in vivo in the OA rat model. TSA treatment demonstrated in vivo efficacy through the attenuation of various OA‑associated molecular and physiological changes. Taken together, the results of the present study suggest that TSA has potential therapeutic value for the treatment of OA.

View Figures

View References

1	Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, Gabriel S, Hirsch R, Hochberg MC, Hunder GG, et al: Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 58:26–35. 2008. View Article : Google Scholar : PubMed/NCBI
2	Felson DT, Chaisson CE, Hill CL, Totterman SM, Gale ME, Skinner KM, Kazis L and Gale DR: The association of bone marrow lesions with pain in knee osteoarthritis. Ann Intern Med. 134:541–549. 2001. View Article : Google Scholar : PubMed/NCBI
3	Goldring MB and Goldring SR: Osteoarthritis. J Cell Physiol. 213:626–634. 2007. View Article : Google Scholar : PubMed/NCBI
4	Chen WP, Bao JP, Hu PF, Feng J and Wu LD: Alleviation of osteoarthritis by Trichostatin A, a histone deacetylase inhibitor, in experimental osteoarthritis. Mol Biol Rep. 37:3967–3972. 2010. View Article : Google Scholar : PubMed/NCBI
5	Neogi T and Zhang Y: Osteoarthritis prevention. Curr Opin Rheumatol. 23:185–191. 2011. View Article : Google Scholar : PubMed/NCBI
6	Lee R and Kean WF: Obesity and knee osteoarthritis. Inflammopharmacology. 20:53–58. 2012. View Article : Google Scholar : PubMed/NCBI
7	Loeser RF: Aging and osteoarthritis. Curr Opin Rheumatol. 23:492–496. 2011. View Article : Google Scholar : PubMed/NCBI
8	Aigner T and McKenna L: Molecular pathology and pathobiology of osteoarthritic cartilage. Cell Mol Life Sci. 59:5–18. 2002. View Article : Google Scholar : PubMed/NCBI
9	Hu PF, Chen WP, Tang JL, Bao JP and Wu LD: Protective effects of berberine in an experimental rat osteoarthritis model. Phytother Res. 25:878–885. 2011. View Article : Google Scholar
10	Loeuille D, Chary-Valckenaere I, Champigneulle J, Rat AC, Toussaint F, Pinzano-Watrin A, Goebel JC, Mainard D, Blum A, Pourel J, et al: Macroscopic and microscopic features of synovial membrane inflammation in the osteoarthritic knee: Correlating magnetic resonance imaging findings with disease severity. Arthritis Rheum. 52:3492–3501. 2005. View Article : Google Scholar : PubMed/NCBI
11	Aigner T, Sachse A, Gebhard PM and Roach HI: Osteoarthritis: Pathobiology-targets and ways for therapeutic intervention. Adv Drug Deliv Rev. 58:128–149. 2006. View Article : Google Scholar : PubMed/NCBI
12	Attur MG, Dave M, Cipolletta C, Kang P, Goldring MB, Patel IR, Abramson SB and Amin AR: Reversal of autocrine and paracrine effects of interleukin 1 (IL-1) in human arthritis by type II IL-1 decoy receptor. Potential for pharmacological intervention. J Biol Chem. 275:40307–40315. 2000. View Article : Google Scholar : PubMed/NCBI
13	Moos V, Fickert S, Müller B, Weber U and Sieper J: Immunohistological analysis of cytokine expression in human osteoarthritic and healthy cartilage. J Rheumatol. 26:870–879. 1999.PubMed/NCBI
14	Bramono DS, Richmond JC, Weitzel PP, Kaplan DL and Altman GH: Matrix metalloproteinases and their clinical applications in orthopaedics. Clin Orthop Relat Res. 272–285. 2004. View Article : Google Scholar : PubMed/NCBI
15	Mandal M, Mandal A, Das S, Chakraborti T and Sajal C: Clinical implications of matrix metalloproteinases. Mol Cell Biochem. 252:305–329. 2003. View Article : Google Scholar : PubMed/NCBI
16	Poole AR: Biochemical/immunochemical biomarkers of osteoarthritis: Utility for prediction of incident or progressive osteoarthritis. Rheum Dis Clin North Am. 29:803–818. 2003. View Article : Google Scholar : PubMed/NCBI
17	Baker AH, Edwards DR and Murphy G: Metalloproteinase inhibitors: Biological actions and therapeutic opportunities. J Cell Sci. 115:3719–3727. 2002. View Article : Google Scholar : PubMed/NCBI
18	Johnston P, Larson D, Clark IM and Chojnowski AJ: Metalloproteinase gene expression correlates with clinical outcome in Dupuytren's disease. J Hand Surg Am. 33:1160–1167. 2008. View Article : Google Scholar : PubMed/NCBI
19	Hayakawa T: Multiple functions of tissue inhibitors of metalloproteinases (TIMPs): A new aspect involving osteoclastic bone resorption. J Bone Miner Metab. 20:1–13. 2002. View Article : Google Scholar : PubMed/NCBI
20	Hernandez-Barrantes S, Bernardo M, Toth M and Fridman R: Regulation of membrane type-matrix metalloproteinases. Semin Cancer Biol. 12:131–138. 2002. View Article : Google Scholar : PubMed/NCBI
21	Kobayashi M, Squires GR, Mousa A, Tanzer M, Zukor DJ, Antoniou J, Feige U and Poole AR: Role of interleukin-1 and tumor necrosis factor alpha in matrix degradation of human osteoarthritic cartilage. Arthritis Rheum. 52:128–135. 2005. View Article : Google Scholar : PubMed/NCBI
22	Aida Y, Maeno M, Suzuki N, Shiratsuchi H, Motohashi M and Matsumura H: The effect of IL-1beta on the expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human chondrocytes. Life Sci. 77:3210–3221. 2005. View Article : Google Scholar : PubMed/NCBI
23	Yoshida M, Kijima M, Akita M and Beppu T: Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem. 265:17174–17179. 1990.PubMed/NCBI
24	Ghosh AK, Mori Y, Dowling E and Varga J: Trichostatin A blocks TGF-beta-induced collagen gene expression in skin fibroblasts: Involvement of Sp1. Biochem Biophys Res Commun. 354:420–426. 2007. View Article : Google Scholar : PubMed/NCBI
25	Piekarz R and Bates S: A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des. 10:2289–2298. 2004. View Article : Google Scholar : PubMed/NCBI
26	Monneret C: Histone deacetylase inhibitors. Eur J Med Chem. 40:1–13. 2005. View Article : Google Scholar : PubMed/NCBI
27	Clayton AL, Hazzalin CA and Mahadevan LC: Enhanced histone acetylation and transcription: A dynamic perspective. Mol Cell. 23:289–296. 2006. View Article : Google Scholar : PubMed/NCBI
28	Kouzarides T: Chromatin modifications and their function. Cell. 128:693–705. 2007. View Article : Google Scholar : PubMed/NCBI
29	Li B, Carey M and Workman JL: The role of chromatin during transcription. Cell. 128:707–719. 2007. View Article : Google Scholar : PubMed/NCBI
30	Chen WP, Bao JP, Tang JL, Hu PF and Wu LD: Trichostatin A inhibits expression of cathepsins in experimental osteoarthritis. Rheumatol Int. 31:1325–1331. 2011. View Article : Google Scholar
31	Matsushita T, Sasaki H, Takayama K, Ishida K, Matsumoto T, Kubo S, Matsuzaki T, Nishida K, Kurosaka M and Kuroda R: The overexpression of SIRT1 inhibited osteoarthritic gene expression changes induced by interleukin-1β in human chondrocytes. J Orthop Res. 31:531–537. 2013. View Article : Google Scholar
32	Zhong HM, Ding QH, Chen WP and Luo RB: Vorinostat, a HDAC inhibitor, showed anti-osteoarthritic activities through inhibition of iNOS and MMP expression, p38 and ERK phosphorylation and blocking NF-kB nuclear translocation. Int Immunopharmacol. 17:329–335. 2013. View Article : Google Scholar : PubMed/NCBI
33	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
34	Li J, Zhou XD, Yang KH, Fan TD, Chen WP, Jiang LF, Bao JP, Wu LD and Xiong Y: Hinokitiol reduces matrix metalloproteinase expression by inhibiting Wnt/β-Catenin signaling in vitro and in vivo. Int Immunopharmacol. 23:85–91. 2014. View Article : Google Scholar : PubMed/NCBI
35	Lee SW, Song YS, Shin SH, Kim KT, Park YC, Park BS, Yun I, Kim K, Lee SY, Chung WT, et al: Cilostazol protects rat chondrocytes against nitric oxide-induced apoptosis in vitro and prevents cartilage destruction in a rat model of osteoarthritis. Arthritis Rheum. 58:790–800. 2008. View Article : Google Scholar : PubMed/NCBI
36	Bulstra SK, Buurman WA, Walenkamp GH and Van der Linden AJ: Metabolic characteristics of in vitro cultured human chondrocytes in relation to the histopathologic grade of osteoarthritis. Clin Orthop Relat Res. 294–302. 1989.PubMed/NCBI
37	Schurigt U, Stopfel N, Hückel M, Pfirschke C, Wiederanders B and Bräuer R: Local expression of matrix metalloproteinases, cathepsins, and their inhibitors during the development of murine antigen-induced arthritis. Arthritis Res Ther. 7:R174–R188. 2005. View Article : Google Scholar : PubMed/NCBI
38	Little CB, Barai A, Burkhardt D, Smith SM, Fosang AJ, Werb Z, Shah M and Thompson EW: Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development. Arthritis Rheum. 60:3723–3733. 2009. View Article : Google Scholar : PubMed/NCBI
39	Adcock IM: HDAC inhibitors as anti-inflammatory agents. Br J Pharmacol. 150:829–831. 2007. View Article : Google Scholar : PubMed/NCBI
40	Strahl BD and Allis CD: The language of covalent histone modifications. Nature. 403:41–45. 2000. View Article : Google Scholar : PubMed/NCBI
41	Lauder SN, Carty SM, Carpenter CE, Hill RJ, Talamas F, Bondeson J, Brennan P and Williams AS: Interleukin-1beta induced activation of nuclear factor-kappab can be inhibited by novel pharmacological agents in osteoarthritis. Rheumatology (Oxford). 46:752–758. 2007. View Article : Google Scholar